H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases

Pediatric tumors are characterized by a consistent H-RAS mutation status, whereas FGFR3 and p53 pathways are not involved in this tumor initiation. These results may explain the few recurrences seen in this population.